News
-
2 min
iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track
-
2 min
iQ-007 Considered as First-in-Class Therapeutic Agent in Prestigious Journal of Medicinal Chemistry
-
2 min
iQure Pharma Secures $600K in Commitments in Early Closing to Research Pain Therapies
-
1 min
iQure Pharma’s Lead Therapeutic Advances in the NIH Preclinical Screening Platform for Pain (PSPP)
-
2 min
iQure Pharma Targets Future with New Board Appointments
-
1 min
iQure Pharma Meets Lipinski’s (Pfizer’s) Rule of Five with Analgesic Compound for Pain
-
1 min
iQure Pharma Will Present at Mid-Atlantic Diamond Venture 2022 Spring Forum
-
1 min
iQure Pharma is Investment-Ready — Will Present at Keiretsu Forum Mid-Atlantic
-
1 min
iQure Pharma Awarded Patent for Therapy to Treat Pain and Epilepsy
-
1 min
iQ-008 Accepted into NIH Preclinical Screening Platform for Pain (PSPP)
-
1 min
Novel and promising mechanism of action for new pain candidate iQ-007 confirmed
